Actelion vs. Torrent: Consent Judgment in Macitentan Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Actelion Pharmaceuticals Ltd. v. Torrent Pharmaceuticals Ltd. |
| Numéro de dossier | 1:24-cv-03990 (D.N.J.) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | March 19, 2024 – April 18, 2024 30 days |
| Résultat | Plaintiff Win — Consent Judgment with Injunction & Validity Admission |
| Brevets en cause | |
| Produits incriminés | Torrent’s generic macitentan 10 mg oral tablets (ANDA No. 211107) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Swiss-headquartered biopharmaceutical company, a subsidiary of Johnson & Johnson, known for its leadership in pulmonary arterial hypertension (PAH) therapies.
🛡️ Défendeur
Global generic pharmaceutical manufacturer based in India, whose U.S. subsidiary filed ANDA No. 211107 for generic macitentan.
Brevets en cause
This landmark case involved two key patents covering the blockbuster PAH drug OPSUMIT® (macitentan), which protect both the active pharmaceutical ingredient and its formulation or methods of use. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US7094781B2 — Covers pharmaceutical compositions and methods relating to macitentan.
- • US10946015B2 — Covers formulation or use claims related to the OPSUMIT® product.
Vous développez un médicament générique ?
Ensure your product does not infringe existing pharmaceutical patents before regulatory submission.
Le verdict et l'analyse juridique
Résultat
The case resolved via **Consent Judgment** in a remarkably swift 30-day period. Torrent Pharmaceuticals expressly **admitted the validity and enforceability** of U.S. Patent No. 7,094,781 and conceded that its proposed generic macitentan product would infringe prior to patent expiration. A **permanent injunction** was entered against Torrent, prohibiting any infringing activity related to ANDA No. 211107.
Principales questions juridiques
This resolution reinforces the potency of the Hatch-Waxman Act, particularly **35 U.S.C. § 271(e)(2)**, which defines the filing of an ANDA for a patented drug as an act of infringement. Torrent’s explicit admission of validity and infringement stands out, as many ANDA litigations result in settlements without such a definitive concession. This binding judicial admission forecloses future challenges related to this ANDA, providing Actelion with robust and expedited protection for its macitentan patent estate in the District of New Jersey, a key venue for pharmaceutical IP disputes.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in pharmaceutical patent litigation. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir les 2 brevets associés à cette technologie
- See which companies are most active in PAH IP
- Understand claim scope and validity patterns
🔍 Vérifier les risques liés à mon produit générique
Run a comprehensive FTO analysis for your own active pharmaceutical ingredient (API) or formulation.
- Input your API description or technical features
- L'IA identifie les brevets de formulation/méthode susceptibles de constituer un obstacle
- Get actionable regulatory pathway risk assessment
Zone à haut risque
Composition of matter patents for macitentan
2 brevets clés
Covering macitentan API & formulation
Conception complexe
Formulation and method of use claims
✅ Points clés à retenir
Consent judgments with explicit validity admissions provide stronger protection than settlements silent on patent merit.
Rechercher la jurisprudence connexe →The District of New Jersey remains the preferred venue for Hatch-Waxman litigation due to judicial familiarity and favorable procedural environment.
Explorer les précédents →A 30-day resolution timeline is achievable in ANDA cases when leverage is clear and both parties are commercially motivated to resolve early.
Analyser les tendances en matière de litiges →Injunction scope should expressly cover affiliates, successors, and assigns to prevent corporate restructuring workarounds.
Review injunction examples →Foire aux questions
The primary patent was U.S. Patent No. 7,094,781 (US7094781B2), designated the “Licensed Patent” in the consent judgment. U.S. Patent No. 10,946,015 (US10946015B2) was also identified among the patents involved in the litigation.
Torrent admitted that US7094781’s claims are valid, enforceable, and would be infringed by commercial activities related to ANDA No. 211107 covering generic macitentan 10 mg tablets. The parties resolved for undisclosed consideration, and a permanent injunction was entered.
It establishes a binding judicial record of US7094781’s validity in the context of ANDA No. 211107, and signals to other potential ANDA challengers that Actelion will enforce its patent estate aggressively and with speed.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- USPTO Patent Full-Text Database — US7094781B2
- PACER Case Lookup — 1:24-cv-03990
- FDA ANDA Database
- U.S. Patent and Trademark Office — Patent Search
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.